Redhill Current Deferred Revenue from 2010 to 2024
| RDHL Stock | USD 7.96 0.05 0.63% |
Current Deferred Revenue | First Reported 2010-12-31 | Previous Quarter 0.9 | Current Value 0.86 | Quarterly Volatility 12.6 M |
Check Redhill Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Redhill Biopharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3 M, Interest Expense of 348.6 K or Selling General Administrative of 18.4 M, as well as many indicators such as Price To Sales Ratio of 34.49, Dividend Yield of 0.0 or PTB Ratio of 102. Redhill financial statements analysis is a perfect complement when working with Redhill Biopharma Valuation or Volatility modules.
Redhill | Current Deferred Revenue |
Latest Redhill Biopharma's Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of Redhill Biopharma over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Redhill Biopharma's Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Redhill Biopharma's overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
Redhill Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 8,923,334 | |
| Geometric Mean | 315,088 | |
| Coefficient Of Variation | 141.51 | |
| Mean Deviation | 8,145,778 | |
| Median | 5,491,000 | |
| Standard Deviation | 12,627,088 | |
| Sample Variance | 159.4T | |
| Range | 41.6M | |
| R-Value | 0.17 | |
| Mean Square Error | 166.6T | |
| R-Squared | 0.03 | |
| Significance | 0.54 | |
| Slope | 488,771 | |
| Total Sum of Squares | 2232.2T |
Redhill Current Deferred Revenue History
About Redhill Biopharma Financial Statements
Redhill Biopharma investors utilize fundamental indicators, such as Current Deferred Revenue, to predict how Redhill Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 0.90 | 0.86 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Redhill Biopharma Correlation against competitors. For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Redhill Biopharma. If investors know Redhill will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Redhill Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (302.63) | Revenue Per Share 4.733 | Quarterly Revenue Growth (0.28) | Return On Assets (0.45) | Return On Equity (17.09) |
The market value of Redhill Biopharma is measured differently than its book value, which is the value of Redhill that is recorded on the company's balance sheet. Investors also form their own opinion of Redhill Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Redhill Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Redhill Biopharma's market value can be influenced by many factors that don't directly affect Redhill Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Redhill Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Redhill Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Redhill Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.